Pasceri Vincenzo, Pristipino Christian, Pelliccia Francesco, Granatelli Antonino, Speciale Giulio, Roncella Adriana, Pironi Bruno, Capasso Michele, Richichi Giuseppe
Interventional Cardiology Unit, San Filippo Neri Hospital, Rome, Italy.
Am J Cardiol. 2005 Jun 1;95(11):1358-61. doi: 10.1016/j.amjcard.2005.01.082.
We tested the effects of the nitric oxide donor nitroprusside as treatment for no reflow in 23 consecutive patients who underwent coronary angioplasty for acute myocardial infarction. No reflow was defined as a decrease of >/=1 Thrombolysis In Myocardial Infarction (TIMI) trial flow grade occurring after successful initial coronary recanalization. Nitroprusside induced a significant improvement in coronary flow, with an increase in TIMI flow grade from 1.5 +/- 0.8 to 2.9 +/- 0.3 (p <0.0001) and in TIMI frame count from 46 +/- 25 to 16 +/- 5 (p <0.0001). There were no significant adverse effects apart from transient hypotension. Intracoronary nitroprusside should be considered as a treatment of no reflow occurring in acute myocardial infarction.
我们对23例因急性心肌梗死接受冠状动脉血管成形术的连续患者，测试了一氧化氮供体硝普钠对无复流的治疗效果。无复流定义为在初始冠状动脉成功再通后，心肌梗死溶栓试验（TIMI）血流分级下降≥1级。硝普钠使冠状动脉血流显著改善，TIMI血流分级从1.5±0.8提高到2.9±0.3（p<0.0001），TIMI帧计数从46±25降至16±5（p<0.0001）。除短暂性低血压外，无显著不良反应。冠状动脉内应用硝普钠应被视为急性心肌梗死中无复流的一种治疗方法。
